C.D.C. Weighs Advising Everyone to Wear a Mask

Widespread use of nonmedical masks could reduce community transmission. But recommending their broad use could also cause a run on the kind of masks that health care workers desperately need.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Masks Protective Clothing and Gear Shortages Coronavirus (2019-nCoV) Health Insurance and Managed Care United States Politics and Government Centers for Disease Control and Prevention National Institute of Allergy and Infectious Diseases F Source Type: news

Related Links:

The U.S. House of Representatives passed a new coronavirus relief package, The Heroes Act, on May 15, 2020. If passed by the Senate and signed by the President, this will be the fifth measure adopted by Congress to respond to the COVID-19 pandemic. The $3 trillion stimulus bill includes $1 trillion in assistance for state, local, territorial, and tribal governments; $75 billion for coronavirus testing, contact tracing, and isolation measures; emergency supplemental appropriations to federal agencies; another round of direct payments; and $200 billion for a “Heroes’ fund” to provide hazard pay for essenti...
Source: Public Policy Reports - Category: Biology Authors: Source Type: news
PMID: 32448437 [PubMed - in process]
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Ann Allergy Asthma Immunol Source Type: research
The results of the present study showed that ruxolitinib plus SoC was well tolerated in the treatment of severe COVID-19. It significantly mitigated exuberant cytokine storm featured in severe COVID-19, with significant chest CT improvement.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
A clinical trial led to the authorization of the only drug shown to work in Covid-19 patients. But until now, few experts had seen the numbers.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drugs (Pharmaceuticals) Remdesivir (Drug) Coronavirus (2019-nCoV) Research Food and Drug Administration Gilead Sciences Inc National Institute of Allergy and Infectious Diseases New England Journal of Medicine Kalil, Andre United States Source Type: news
On April 29th Anthony Fauci announced the National Institute of Allergy and Infectious Diseases, an institute he runs, had completed a study of the antiviral remdesivir for COVID-19. The drug reduced time to recovery from 15 to 11 days, he said, a breakthrough proving“a drug can block this virus.” Now people are clamoring for […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Meds COVID-19 coronavirus Infectious Disease Medications Source Type: blogs
At the time of this writing, April 7, 2020, more than 1.2 million people worldwide are infected and more than 68,000 have died because of coronavirus disease 2019 (COVID-19) induced by the novel severe acute respiratory syndrome coronavirus 2 infection, and this figure will surely multiply in the next few weeks according to Dr Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases. Severe acute respiratory syndrome coronavirus 2 uses angiotensin-converting enzyme-2 (ACE-2) (a type I transmembrane metallocarboxypeptidase) as its preferred entry receptor.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
Because of the great transmissibility of the virus causing coronavirus disease 2019 (COVID-19), the use of small-volume nebulizers (SVNs) in these days may constitute a serious hazard.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research
ConclusionWe confirm that aerosolization presents a risk to the endonasal skull base surgeon. In the outpatient setting, use of a barrier significantly reduces aerosol spread. Cold surgical instrumentation and microdebrider use pose significantly less aerosolization risk than a high ‐speed drill. Procedures requiring drill use should carry a special designation as an “aerosol‐generating surgery” to convey this unique risk, and this supports the need for protective personal protective equipment.
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.” T...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature Magazine Source Type: news
From her laboratory in the far western reaches of Montana, Elizabeth Fischer is trying to help people see what they’re up against in COVID-19. Over the past three decades, Fischer, 58, and her team at the Rocky Mountain Laboratories, part of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases, have captured and created some of the more dramatic images of the world’s most dangerous pathogens. “I like to get images out there to try to convey that this is an entity, to try to demystify it, so this is something more tangible for people,” says Fischer, on...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Allergy | Allergy & Immunology | Centers for Disease Control and Prevention (CDC) | Coronavirus | COVID-19 | Government | Health | Health Insurance | Health Management | Infectious Diseases | Insurance | Managed Care | Politics | USA Health